Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
Read GH, Pacheco JV, Baumann B, Richards ZA, Deaton R, Macias V, Kajdacsy-Balla A, Kittles R, Abern MR, Nonn L. Dysregulation of estrogen signaling and HSD17B7 in the prostate stroma of African American men. Endocrinology. 2026 Feb 04; 167(3).
-
Li JL, Zhang H, Wang X, Jia G, McClellan JC, Guo W, Sun Y, Fiorica PN, Ambs S, Barnard ME, Chen Y, Garcia-Closas M, Gu J, Hu JJ, John EM, Nathanson KL, Nemesure B, Pal T, Shu XO, Press MF, Sanderson M, Sandler DP, Troester MA, Yao S, Long J, Ahearn TU, Brewster AM, Falusi A, Kraft P, Hennis AJM, Makumbi T, Mapoko BSE, O'Brien KM, Ojengbede O, Olshan AF, Reid S, Zirpoli G, Cai Q, Butler EN, Huang M, Obafunwa J, Weinberg CR, Ambrosone C, Ping J, Tao R, Li B, Guo X, Gao G, Conti DV, Chatterjee N, Palmer JR, Olopade OI, Zheng W, Haiman CA, Huo D. Improved polygenic risk prediction models for breast cancer subtypes in women of African ancestry. Nat Genet. 2026 Mar; 58(3):560-569.
-
Shi X, Yan G, Zhao NC, Wang Q, Lu D, Lawler D, Gahtani RM, Byrne C, Haddad BR, Copeland RL, Martin MB. Calcium and Cadmium Activate ESRRB to Mediate Cell Stemness and Pluripotency. Int J Mol Sci. 2025 Dec 25; 27(1).
-
Plagens RN, Tirado CSR, Li S, Maldonado-Vazquez N, Montes-Rodriguez IM, Dutil J, Mills CA, Herring LE, Franco HL. Mapping the FOXA1 Interactome in ER+ Breast Cancer Cells Using Proximity Labeling Reveals Novel Interactions with the Orphan Nuclear Receptor NR2C2. Mol Cancer Res. 2025 Dec 02; 23(12):997-1011.
-
Fujii T, Iwase T, Shen Y, Fukui J, Ueno NT. Reconsidering the definition of triple-negative breast cancer in the immune checkpoint inhibitor era: an optimal cut-off value for hormone receptor percentage of HER2-negative invasive breast cancer. Br J Cancer. 2026 Jan; 134(1):1-7.
-
Kwa M, Hussey G, Novik Y, Franke AA, Volkova A, Flores K, Blaser MJ, Speyer J, Oratz R, Meyers M, Jhaveri K, Fadel E, Heguy A, Schluter J, Ruggles KV, Adams S. Evaluation of the gut microbiome and sex hormones in postmenopausal women with newly diagnosed hormone receptor-positive breast cancer versus healthy women: a prospective case-control study. J Cancer Res Clin Oncol. 2025 Oct 04; 151(10):275.
-
Xia K, Chen E, Hu R, Pagano I, Fukui J. Applicability of Oncotype DX Testing in a Diverse Breast Cancer Population in Hawaii. Breast J. 2025; 2025:9104103.
-
Belgodere JA, Elliott JR, Benz MC, Kpeli GW, Elliott S, Ponder IJ, Sanga Pema GER, Ma P, Dietrich SR, Cheng T, Nguyen K, Tilghman SL, Zou B, Anbalagan M, Rowan BG, Newman RH, Mondrinos M, Sridhar J, Wiese TE, Ali S, Hoang VT, Collins-Burow BM, Martin EC, Abbas HK, Bou? SM, Burow ME. Modulation of Estrogen Receptor Activity by the Phytoalexin Tuberosin Produced from Elicited Kudzu (Pueraria lobata). J Nat Prod. 2025 Jul 25; 88(7):1568-1580.
-
Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precis Oncol. 2025 Jun; 9:e2400776.
-
Fu Z, Borho L, Taylor SE, Kelemen LE, DeFazio A, Webb PM, K?bel M, Meagher NS, Na R, Antoniou AC, Brand AH, Kennedy CJ, Nevins N, Pharoah PDP, Shvetsov YB, Winham SJ, Alsop J, Beckmann MW, Bolithon A, Boros J, Bowtell DDL, Brenton JD, Carney ME, Chudecka-Glaz A, Cook LS, Cybulski C, Fasching PA, Fereday S, Fortner RT, Garc?a MJ, Goode EL, Goodman MT, Gronwald J, Hartmann A, Hernandez BY, H?gdall E, Huntsman DG, Jensen A, Jimenez-Linan M, Joseph JM, Karlan BY, Kaznowska E, Kjaer SK, Kluz T, Koziak JM, Lester J, Longacre TA, Lycke M, McGuire V, Moysich KB, Murphy RA, Orsulic S, Ramus SJ, Rodr?guez-Antona C, Rothstein JH, Samra S, Sieh W, Steed H, Sundfeldt K, Talhouk A, Ucinski J, Wang C, Wentzensen N, Whittemore AS, Wilkens LR, Songer T, Brooks MM, Tang L, Modugno F. Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis. Gynecol Oncol. 2025 07; 198:112-129.